Effective April 1, 2025, MORL’s updated genetic testing panels will enhance precision and support for patients with hearing loss and complement-mediated renal diseases.

New OtoSCOPE Report 2025 - User Friendly Guide

New Genetic Renal Panel 2025 - User Friendly Guide

Key Updates:

  • Enhanced Genetic Report Templates: Our genetic reports are being updated to improve clarity and usability. Watch the videos above for details. A downloadable guide is also available for OtoSCOPE and Genetic Renal Panel 
  • Transition to GRCh38 Genome: We are moving to the latest human reference genome, GRCh38. This update ensures our testing reflects the most up-to-date understanding of genes covered on our panels, coupled with the latest version of reference population data (gnomAD v4.1.0).
  • Expanded Coverage: We have expanded the coverage of intronic regions flanking each exon to increase the detection of variants that may impact splicing.

What Remains Unchanged

  • Gene Coverage: OtoSCOPE® will continue to include 224 genes, and the Genetic Renal Panel will maintain its 13 gene-panel coverage.
  • Detailed Case-by-Case Review: MORL promotes precision medicine by ensuring expert, comprehensive review for each patient. Our multidisciplinary Hearing and Renal Teams carefully integrate phenotypic and genotypic data by discussing clinical information, family history, and genetic testing results to provide expert-driven, personalized results for your patients and families. 
  • Turnaround Time: Results will continue to be delivered within 6 weeks for OtoSCOPE® and 3 weeks for the Genetic Renal Panel. 
  • Cost of Testing: The cost of testing for both OtoSCOPE® and the Genetic Renal Panel will remain unchanged with these updates. See please our test menu for details.